RICHLAND, Wash.--(BUSINESS WIRE)--June 28, 2005-- Company anticipates increased demand for new Cesium-131 treatment option for prostate and other soft tissue cancers IsoRay Medical, Inc., the manufacturer and distributor of a new brachytherapy seed isotope for the treatment of prostate cancer, has closed its final round of angel and private capital fundraising, said Roger Girard, chairman and CEO. Girard said the company has raised more than $10 million in debt and equity over the last 18 months through a private offering. The next round of funding through institutional and public sectors is scheduled for October 2005.
